HUTCHMED Completes FDA Submission for High-Potential Colorectal Cancer Drug | BioSpace

HUTCHMED has completed the rolling submission of its New Drug Application to the FDA for fruquintinib, its candidate for refractor metastatic colorectal cancer.

Read the full article here

Related Articles